Page last updated: 2024-11-13
6-O-feruloylcatalpol
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 24121289 |
| CHEMBL ID | 2332349 |
| CHEBI ID | 69800 |
Synonyms (24)
| Synonym |
|---|
| 770721-33-0 |
| ACON1_001535 |
| NCGC00180405-01 |
| MEGXP0_001245 |
| 6-feruloylcatalpol |
| 6-o-trans-feruloylcatalpol |
| 6-o-feruloylcatalpol |
| CHEBI:69800 , |
| CHEMBL2332349 |
| AC-34418 |
| Q-100737 |
| [(1as,1bs,2s,5ar,6s,6as)-1a-(hydroxymethyl)-2-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2,5a,6,6a-tetrahydro-1bh-oxireno[5,6]cyclopenta[1,3-c]pyran-6-yl] (e)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoate |
| NCGC00180405-03 |
| [(1s,2s,4s,5s,6r,10s)-2-(hydroxymethyl)-10-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,9-dioxatricyclo[4.4.0.02,4]dec-7-en-5-yl] (e)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoate |
| AKOS032948187 |
| Q27138141 |
| FS-9027 |
| 6-o-e-feruloylcatalpol |
| amphicoside iii |
| E88807 |
| DTXSID001346770 |
| HY-N2712 |
| 6''-o-trans-feruloylcatalpol |
| CS-0023183 |
Research Excerpts
Bioavailability
| Excerpt | Reference | Relevance |
|---|---|---|
| "The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Roles (1)
| Role | Description |
|---|---|
| metabolite | Any intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Drug Classes (1)
| Class | Description |
|---|---|
| hydroxycinnamic acid | Any member of the class of cinnamic acids carrying one or more hydroxy substituents. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Bioassays (12)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1347160 | Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1347159 | Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1301499 | Cytotoxicity against human Bel7402 cells by MTT assay | 2016 | Journal of natural products, Feb-26, Volume: 79, Issue:2 | Bioactive Iridoid Glycosides from the Whole Plants of Rehmannia chingii. |
| AID1301500 | Cytotoxicity against human BGC823 cells by MTT assay | 2016 | Journal of natural products, Feb-26, Volume: 79, Issue:2 | Bioactive Iridoid Glycosides from the Whole Plants of Rehmannia chingii. |
| AID1378838 | Peroxynitrite scavenging activity assessed as inhibition of DHR 123 oxidation after 5 mins in presence of SIN-1 by fluorescence assay | 2017 | Journal of natural products, 08-25, Volume: 80, Issue:8 | Peroxynitrite-Scavenging Glycosides from the Stem Bark of Catalpa ovata. |
| AID1301501 | Cytotoxicity against human A2780 cells by MTT assay | 2016 | Journal of natural products, Feb-26, Volume: 79, Issue:2 | Bioactive Iridoid Glycosides from the Whole Plants of Rehmannia chingii. |
| AID730648 | Binding affinity to recombinant Hsp90 alpha (unknown origin) by surface plasmon resonance | 2013 | Journal of medicinal chemistry, Feb-28, Volume: 56, Issue:4 | A chemical-biological study reveals C9-type iridoids as novel heat shock protein 90 (Hsp90) inhibitors. |
| AID1301497 | Cytotoxicity against human A549 cells by MTT assay | 2016 | Journal of natural products, Feb-26, Volume: 79, Issue:2 | Bioactive Iridoid Glycosides from the Whole Plants of Rehmannia chingii. |
| AID1301498 | Cytotoxicity against human HT-29 cells by MTT assay | 2016 | Journal of natural products, Feb-26, Volume: 79, Issue:2 | Bioactive Iridoid Glycosides from the Whole Plants of Rehmannia chingii. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (6)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.56
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||